Positive Phase II results clear the way for Phase III development, but a successful transition involves far more than scaling up the clinical program.
Consider what can happen when a study expands into new countries. A market that looks promising based on patient availability may have a different standard of care that affects the protocol, requires additional drug sourcing, and introduces new supply and import requirements. What begins as a country-selection decision quickly becomes a clinical, regulatory, and supply decision as well.
That is the less obvious challenge of moving into Phase III. The study gets larger, certainly, with more patients, sites, countries, and investigational product. But the more consequential shift is how much more interconnected the development program becomes.
Country and site considerations, formulation and manufacturing requirements, supply complexity, and regulatory dependencies begin to converge. A decision in one area can create requirements or constraints in another.
Phase III readiness, then, is about more than whether the clinical evidence supports moving forward. It requires understanding what needs to change across the development program, which decisions depend on one another, and what can be put in motion before Phase II is complete.
Country selection has downstream consequences
As Phase III expands across countries, the criteria for where to conduct the study become more complex. Patient availability and enrollment potential matter, but they are only part of the decision.
Standard of care can vary considerably between countries, including which therapies patients receive, how those treatments are reimbursed, and whether they are readily available. Those differences can affect protocol feasibility, patient participation, and what medications may need to be sourced and provided as part of the study.
In some cases, there are ethical considerations as well. If patients routinely receive a therapy as standard of care in one country, the study plan needs to account for how that treatment will be provided and what happens when study participation ends.
Competition for patients adds another variable. A country with an attractive patient population and experienced sites may look very different when multiple trials are recruiting from the same pool. Treatment practices and protocol requirements can affect sourcing and supply, while each additional country brings its own regulatory, import, and export requirements.
The question, then, is not simply where patients can be found. It is where the study can be executed successfully once the full set of clinical, regulatory, and supply requirements is taken into account.
The product may need to evolve along with the clinical program
Phase III readiness can also require a fresh look at the investigational product itself.
A formulation appropriate for one population may not be appropriate for another. A program expanding from adults into pediatrics, for example, may require a different formulation. Emerging Phase II data may also inform dose or other product requirements for the pivotal study.
A change that sounds relatively contained can quickly extend into other parts of development. A new formulation may require additional development work, new or scaled batches, and changes to regulatory documentation.
Identifying these requirements late can put that work directly on the critical path. If a formulation change is still being defined as the Phase III study is being finalized, there may be little room to absorb the additional development and manufacturing work it requires.
Anticipating likely requirements creates more room to act. While Phase II is still underway, teams can identify the development and manufacturing work that may be needed and determine which activities can move forward with the information already available.
Some decisions will need to wait for additional evidence. Others can be advanced earlier, reducing the amount of work left to begin once the path to Phase III is clear.
Manufacturing has to scale, too
The same principle applies to manufacturing capacity.
A manufacturing strategy that is entirely appropriate for early clinical development may not be able to support the volume or requirements of a global Phase III program. Moving forward may require scaling into a different facility or transferring the process to another manufacturer.
A technology transfer or change in manufacturing strategy can also trigger regulatory updates. In the U.S., that can mean changes to the IND; in Europe, updates to the IMPD may be required. The CMC documentation needed to support those updates can also influence the timing of clinical regulatory submissions and study start-up.
This creates an opportunity to plan the work in parallel rather than sequentially. For example, regulatory drafts can advance against available information while final CMC source documents are being completed, reducing the amount of work left once the last critical input is available.
Clinical, regulatory, and manufacturing teams can align on critical inputs early, advance drafts as information becomes available, and prioritize the documents needed to keep the Phase III program moving.
Phase III readiness depends on more than having a manufacturing plan, a regulatory plan, and a clinical plan. Those plans need to account for where, and when, they depend on one another.
Prepare without getting ahead of the evidence
There is an understandable logic to treating Phase II and Phase III sequentially: complete the Phase II study, evaluate the results, make the go/no-go decision, and then prepare for Phase III.
But much of that preparation does not require waiting for the final Phase II readout.
Potential countries and sites can be evaluated, manufacturing capacity assessed, and formulation and regulatory requirements anticipated. Phase III protocol concepts and synopses can begin to take shape. Clear go/no-go criteria can also establish in advance what evidence will trigger the next set of decisions.
As Phase II data emerge, those plans can become more specific. Interim analyses may inform dosing and move the Phase III protocol closer to finalization. Clinical supply activities can be planned against anticipated regulatory milestones, including identifying where work can appropriately advance at risk to support earlier site activation.
The key is knowing which decisions genuinely depend on the evidence and which activities can responsibly move forward while the data are still emerging. That does not require assuming a positive Phase II outcome. It allows appropriate work to move forward while the evidence is still emerging, reducing what remains once the path to Phase III is clear.
Readiness depends on seeing the whole program
A program can be progressing within each individual function and still encounter delays where those functions meet. Preparing for Phase III therefore requires looking ahead while Phase II is still underway and asking what will need to be true across the development program if the data support moving forward.
Where might the formulation need to change? Can the manufacturing strategy support pivotal scale? Which countries make sense once standard of care, competition, supply, and regulatory requirements are considered together? What documentation will be needed, and when? Which activities can begin now, and which should remain contingent on the data?
These questions cannot be answered effectively in isolation. Clinical development, regulatory, manufacturing, and clinical supply decisions need to be made with an understanding of how they affect one another and where one activity depends on another.
That broader view creates room to make better-informed decisions earlier, preserve options where uncertainty remains, and address potential constraints before they disrupt the program.
Phase II success creates the opportunity to advance. Phase III readiness determines how prepared the broader development program is to take the next step.
Preparing for Phase III? Learn how Accelerator™ Drug Development brings clinical development and manufacturing together to help teams anticipate dependencies, coordinate critical activities, and prepare for what comes next.
